FDA Approves Liquid ADHD Drug, Supplemental Indication for Sorilux

The Food and Drug Administration recently approved Quillivant XR for treating attention deficit hyperactivity disorder (ADHD) and approved an additional indication for Sorilux for the topical treatment of plaque psoriasis of the scalp.

NextWave Pharmaceuticals Inc. Oct. 1 announced that FDA approved Quillivant XR (methylphenidate hydrochloride) for extended-release oral suspension.

Quillivant XR is approved for treating ADHD, the company said. The product is the first once-daily, extended-release liquid methylphenidate available for patients with ADHD.

“We are pleased with the FDA’s approval of Quillivant XR and believe it will address an important need for many patients with ADHD and their caregivers,” ...